XUP.STU Genfit SA

Healthcare Biotechnology Stuttgart Exchange
10.80 EUR
Close of Oct 31, 2026
3.41 15.40
Market cap
EUR 540M
P/E
-
P/B
3.35x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is XUP.STU undervalued?

Graham number

The Graham number of Genfit SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genfit SA fundamental analysis

No fundamental analysis for Genfit SA yet.

Genfit SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genfit SA

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemi…

Full company profile